When moyamoya vasculopathy results from an associated disease, this vasculopathy is then referred to as moyamoya syndrome. Moyamoya syndrome has been reported in association with sickle cell disease, neurofibromatosis type 1, Down syndrome, radiation exposure, and other predisposing factors. Other than sickle cell disease, rare hemoglobinopathies, such as hemoglobin Fairfax and hemoglobin Alesha, have been reported to occur with moyamoya. We present a case of moyamoya syndrome associated with an unstable hemoglobinopathy, hemoglobin Southampton (Casper). This is the first reported case of moyamoya associated with this hemoglobinopathy.

Keywords:
Hemoglobinopathy, Moyamoya, Pial synangiosis
1.
Agrawal N, Johnston SC, Wu YW, Sidney S, Fullerton HJ: Imaging data reveal a higher pediatric stroke incidence than prior US estimates. Stroke 2009;40:3415-3421.
2.
Fox CK, Johnston SC, Sidney S, Fullerton HJ: High critical care usage due to pediatric stroke: results of a population-based study. Neurology 2012;79:420-427.
3.
Numis AL, Fox CK: Arterial ischemic stroke in children: risk factors and etiologies. Curr Neurol Neurosci Rep 2014;14:422.
4.
Marden FA, Putman CM, Grant JM, Greenberg J: Moyamoya disease associated with hemoglobin Fairfax and beta-thalassemia. Pediatr Neurol 2008;38:130-132.
5.
Scott RM, Smith ER: Moyamoya disease and moyamoya syndrome. N Engl J Med 2009;360:1226-1237.
6.
Oshima H, Katayama Y: Discovery of cerebrovascular moyamoya disease: research during the late 1950s and early 1960s. Childs Nerv Syst 2012;28:497-500.
7.
Suzuki J, Takaku A: Cerebrovascular ‘moyamoya' disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969;20:288-299.
8.
Veeravagu A, Guzman R, Patil CG, Hou LC, Lee M, Steinberg GK: Moyamoya disease in pediatric patients: outcomes of neurosurgical interventions. Neurosurg Focus 2008;24:E16.
9.
Smith ER, Scott RM: Surgical management of moyamoya syndrome. Skull Base 2005;15:15-26.
10.
Scott RM, Smith JL, Robertson RL, Madsen JR, Soriano SG, Rockoff MA: Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 2004;100:142-149.
11.
Zipfel GJ, Fox DJ Jr, Rivet DJ: Moyamoya disease in adults: the role of cerebral revascularization. Skull Base 2005;15:27-41.
12.
Brockmann K, Stolpe S, Fels C, Khan N, Kulozik AE, Pekrun A: Moyamoya syndrome associated with hemolytic anemia due to Hb Alesha. J Pediatr Hematol Oncol 2005;27:436-440.
13.
Hyde RD, Hall MD, Wiltshire BG, Lehmann H: Haemoglobin Southampton, 106 (G8) Leu leads to pro: an unstable variant producing severe haemolysis. Lancet 1972;ii:1170-1172.
14.
Jones RT, Koler RD, Duerst M, Stocklen Z: Hemoglobin Casper G8 106 leu leads to pro: further evidence that hemoglobin mutations are not random. Adv Exp Med Biol 1972;28:79-98.
15.
Avalos Gómez V, Eandi Eberle S, Pepe C, Sciuccati G, García Rosolen N, Cervio C, Díaz L, Candás A, Bonduel M, Piazza G, Chaves D, Feliú Torres A: Severe hemolytic anemia due to hemoglobin Southampton: case report (in Spanish). Arch Argent Pediatr 2012;110:e91-e94.
16.
Didkovskii NA, Idel'son LI, Filippova AV, Lemann G: A new case of the unstable hemoglobin Southampton-Casper (beta106) (G68) leucine-proline) (in Russian). Probl Gematol Pereliv Krovi 1976;21:48-50.
17.
Eandi Eberle S, Noguera NI, Sciuccati G, Bonduel M, Díaz L, Staciuk R, Feliu-Torres A: Hb Southampton [beta106(G8)Leu->Pro, CTG->CCG] in an Argentinean boy. Hemoglobin 2006;30:401-403.
18.
Heintz NH, Howard PL: Hemoglobin Southampton (Casper): characterization of the base mutation. Am J Hematol 1989;30:1-3.
19.
Wajcman H, Gacon G, Labie D, Koler RD, Jones RT: Isolation and functional characterization of hemoglobin Casper: beta106(G8) Leu replaced by Pro. Biochemistry 1975;14:5017-5020.
20.
Sanefuji M, Ohga S, Kira R, Yoshiura T, Torisu H, Hara T: Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia. J Child Neurol 2006;21:75-77.
21.
Holz A, Woldenberg R, Miller D, Kalina P, Black K, Lane E: Moyamoya disease in a patient with hereditary spherocytosis. Pediatr Radiol 1998;28:95-97.
22.
Schilling RF: Spherocytosis, splenectomy, strokes, and heat attacks. Lancet 1997;350:1677-1678.
23.
Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD: Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006;96:488-491.
24.
Tokunaga Y, Ohga S, Suita S, Matsushima T, Hara T: Moyamoya syndrome with spherocytosis: effect of splenectomy on strokes. Pediatr Neurol 2001;25:75-77.
25.
Setty BN, Stuart MJ, Dampier C, Brodecki D, Allen JL: Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet 2003;362:1450-1455.
26.
Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W, et al: Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992;90:2333-2339.
27.
Crary SE, Buchanan GR: Vascular complications after splenectomy for hematologic disorders. Blood 2009;114:2861-2868.
28.
Karvandian K, Khan ZH, Zebardast J, Miri SR: Laparoscopic splenectomy in a child with moyamoya syndrome, hereditary spherocytosis, and interstitial lung disease: a mere coincidence or partnership based on genetic similarities. Case Rep Anesthesiol 2011;2011:253434.
29.
Tagawa T, Naritomi H, Mimaki T, Yabuuchi H, Sawada T: Regional cerebral blood flow, clinical manifestations, and age in children with moyamoya disease. Stroke 1987;18:906-910.
30.
Ellenbogen RG, Abdulrauf SI, Sekha LN: Causes of nontraumatic hemorrhagic stroke in children: pediatric moyamoya syndrome; in Ellenbogen RG, Abdulrauf SI, Sekha LN (eds): Principles of Neurological Surgery. Philadelphia, Saunders/Elsevier, 2012, pp 187-194.
31.
Hankinson TC, Bohman LE, Heyer G, Licursi M, Ghatan S, Feldstein NA, Anderson RC: Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J Neurosurg Pediatr 2008;1:211-216.
32.
Jea A, Smith ER, Robertson R, Scott RM: Moyamoya syndrome associated with down syndrome: outcome after surgical revascularization. Pediatrics 2005;116:e694-e701.
33.
Rosser TL, Vezina G, Packer RJ: Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005;64:553-555.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.